nach oben

Erschienen in:

01.12.2021 | Original Article

Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

verfasst von: Kara L. Holloway-Kew, Amelia G. Betson, Kara B. Anderson, James Gaston, Mark A. Kotowicz, Wan-Hui Liao, Maciej Henneberg, Julie A. Pasco

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Summary

Angiotensin-converting enzyme inhibitor use in women was associated with lower femoral neck and lumbar spine bone mineral density as well as trabecular bone score compared to non-users. No differences were identified for men or for those who used ARB medications.

Purpose

Many individuals at high fracture risk use medications such as angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) that could affect bone; thus, this study aimed to investigate whether there are any differences in bone mineral density (BMD) and trabecular bone score (TBS) between ACEI users, ARB users, and non-users.

Methods

Participants (685 men, 573 women) were from the Geelong Osteoporosis Study. Current medication use was self-reported. BMD at the femoral neck (FNBMD) and lumbar spine (LSBMD) were measured using DXA. TBS was calculated using TBS iNsight software. Linear regression models were used to investigate associations between ACEI or ARB use and bone measures, adjusting for other potential confounders. Due to interaction terms, data were stratified by age.

Results

There were 88 (12.8%) men and 41 (7.2%) women taking an ACEI medication, and 71 (10.4%) men and 76 (13.3%) women taking an ARB medication. Compared to non-users, ACEI use was associated with lower FNBMD (− 7.2%), LSBMD (− 12.2%), and TBS (− 9.0%) for women aged < 65 years. Lower TBS was also observed for women aged ≥ 65 years (− 17.3%). No differences were identified for ARB use.

Conclusions

Women who used an ACEI medication had lower values for FNBMD, LSBMD and TBS compared to non-users. No differences were identified for men or for those who used ARB medications.

Ghosh M, Majumdar SR (2014) Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis. Endocrine 46:397–405. https://doi.org/10.1007/s12020-014-0167-4CrossRefPubMed

Bislev LS, Sikjær T, Rolighed L, Rejnmark L (2015) Relationship between aldosterone and parathyroid hormone, and the effect of angiotensin and aldosterone inhibition on bone health. Clin Rev Bone Miner Metab 13:194–205. https://doi.org/10.1007/s12018-015-9182-0CrossRef

Unger T, Stoppelhaar M (2007) Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 100:S25–S31. https://doi.org/10.1016/j.amjcard.2007.05.011CrossRef

National Heart Foundation of Australia (2016) Guideline for the diagnosis and management of hypertension in adults - 2016. Melbourne: National Heart Foundation of Australia

Tamargo J, Caballero R, Delpón E (2015) The renin–angiotensin system and bone. Clin Rev Bone Miner Metab 13:125–148. https://doi.org/10.1007/s12018-015-9189-6CrossRef

Kwok T, Leung J, Zhang YF et al (2012) Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int 23:2159–2167. https://doi.org/10.1007/s00198-011-1831-7CrossRefPubMed

Krieger NS, Frick KK, Bushinsky DA (2004) Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens 13:423–436CrossRef

Asaba Y, Ito M, Fumoto T et al (2009) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24:241–250. https://doi.org/10.1359/jbmr.081006CrossRefPubMed

Shimizu H, Nakagami H, Osako MK et al (2009) Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res 32:786–790. https://doi.org/10.1038/hr.2009.99CrossRefPubMed

10.

Kang KY, Kang Y, Kim M et al (2013) The effects of antihypertensive drugs on bone mineral density in ovariectomized mice. J Korean Med Sci 28:1139–1144. https://doi.org/10.3346/jkms.2013.28.8.1139CrossRefPubMedPubMedCentral

11.

Donmez BO, Ozdemir S, Sarikanat M et al (2012) Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Reports 64:878–888. https://doi.org/10.1016/S1734-1140(12)70882-4CrossRef

12.

Lynn H, Kwok T, Wong SYS et al (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–588. https://doi.org/10.1016/j.bone.2005.09.011CrossRefPubMed

13.

Zhang Y, Qin L, Leung P, Kwok TCY (2012) The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab 30:666–673. https://doi.org/10.1007/s00774-012-0363-3CrossRefPubMed

14.

Rianon N, Ambrose CG, Pervin H et al (2017) Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men. Arch Osteoporos 12:94. https://doi.org/10.1007/s11657-017-0387-3CrossRefPubMedPubMedCentral

15.

Pasco JA, Nicholson GC, Kotowicz MA (2012) Cohort Profile: Geelong Osteoporosis Study. Int J Epidemiol 41:1565–1575CrossRef

16.

Adverse Drug Reactions Advisory Committee (1999) Australian Adverse Drug Reactions Bulletin. 18:1–4

17.

Martineau P, Silva BC, Leslie WD (2017) Utility of trabecular bone score in the evaluation of osteoporosis. Curr Opin Endocrinol Diabetes Obes 24:402–410. https://doi.org/10.1097/med.0000000000000365CrossRefPubMed

18.

Giles GG, Ireland PD (1996) Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne. Cancer Counc Victoria

19.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRef

20.

Henry MJ, Pasco JA, Korn S et al (2010) Bone mineral density reference ranges for Australian men: Geelong Osteoporosis Study. Osteoporos Int 21:909–917CrossRef

21.

Henry MJ, Pasco JA, Pocock NA et al (2004) Reference ranges for bone densitometers adopted Australia-wide: Geelong osteoporosis study. Australas Radiol 48:473–475CrossRef

22.

Anderson KB, Holloway-Kew KL, Hans D et al (2019) Reference ranges for trabecular bone score in Australian men and women: a cross-sectional study. JBMR Plus 3:e10133. https://doi.org/10.1002/jbm4.10133CrossRefPubMedPubMedCentral

23.

Choi HJ, Park C, Lee Y-K et al (2015) Risk of fractures in subjects with antihypertensive medications: a nationwide claim study. Int J Cardiol 184:62–67. https://doi.org/10.1016/j.ijcard.2015.01.072CrossRefPubMed

24.

Solomon DH, Mogun H, Garneau K, Fischer MA (2011) Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 26:1561–1567. https://doi.org/10.1002/jbmr.356CrossRefPubMed

25.

Kwok T, Leung J, Barrett-Connor E, Group for the OF in M (MrOS) R (2017) ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men. Age Ageing 46:57–64. https://doi.org/10.1093/ageing/afw150CrossRefPubMed

26.

Bokrantz T, Schiöler L, Boström KB et al (2020) Antihypertensive Drug Classes and the Risk of Hip Fracture: Results From the Swedish Primary Care Cardiovascular Database. J Hypertens 38:167–175CrossRef

27.

Butt DA, Mamdani M, Gomes T et al (2014) Risk of osteoporotic fractures with angiotensin II receptor blockers versus angiotensin-converting enzyme inhibitors in hypertensive community-dwelling elderly. J Bone Miner Res 29:2483–2488. https://doi.org/10.1002/jbmr.2271CrossRefPubMed

28.

Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case–control study. J Hypertens 24

29.

Kao Y-T, Huang C-Y, Fang Y-A, Liu J-C (2020) The association between renin angiotensin aldosterone system blockers and future osteoporotic fractures in a hypertensive population - a population-based cohort study in Taiwan. Int J Cardiol 305:147–153. https://doi.org/10.1016/j.ijcard.2019.12.069CrossRefPubMed

30.

Carbone LD, Vasan S, Prentice RL et al (2019) The renin-angiotensin aldosterone system and osteoporosis: findings from the Women’s Health Initiative. Osteoporos Int 30:2039–2056. https://doi.org/10.1007/s00198-019-05041-3CrossRefPubMed

31.

Chen C-I, Yeh J-S, Tsao N-W et al (2017) Association between renin-angiotensin-aldosterone system blockade and future osteoporotic fracture risk in hypertensive population: a population-based cohort study in Taiwan. Medicine (Baltimore) 96:e8331–e8331. https://doi.org/10.1097/MD.0000000000008331CrossRefPubMedCentral

32.

Shea C, Witham MD (2020) Association between the use of angiotensin-blocking medications with hip fracture and death in older people. J Frailty Aging 9:107–110. https://doi.org/10.14283/jfa.2019.38CrossRefPubMed

33.

Kunutsor SK, Blom AW, Whitehouse MR et al (2017) Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies. Eur J Epidemiol 32:947–959. https://doi.org/10.1007/s10654-017-0285-4CrossRefPubMedPubMedCentral

34.

Ruths S, Bakken MS, Ranhoff AH et al (2015) Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study. BMC Geriatr 15:153. https://doi.org/10.1186/s12877-015-0154-5CrossRefPubMedPubMedCentral

35.

Pérez-Castrillón JL, Silva J, Justo I et al (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16:453–459. https://doi.org/10.1016/S0895-7061(03)00845-8CrossRefPubMed

36.

Steckelings UM, Kaschina E, Unger T (2005) The AT2 receptor—a matter of love and hate. Peptides 26:1401–1409. https://doi.org/10.1016/j.peptides.2005.03.010CrossRefPubMed

37.

Pasco JA, Kotowicz MA, Henry MJ, Nicholson GC, Spilsbury HJ, Box JDSH (2006) High sensitivity C-reactive protein and fracture risk in elderly women. JAMA 296:1353–1355CrossRef

38.

Quinn JMW, Gillespie MT (2005) Modulation of osteoclast formation. Biochem Biophys Res Commun 328:739–745. https://doi.org/10.1016/j.bbrc.2004.11.076CrossRefPubMed

39.

Tanabe N, Ito-Kato E, Suzuki N et al (2004) IL-1α affects mineralized nodule formation by rat osteoblasts. Life Sci 75:2317–2327. https://doi.org/10.1016/j.lfs.2004.04.026CrossRefPubMed

40.

Liao W-H, Suendermann C, Steuer AE et al (2018) Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity. JCI Insight 3:e99015. https://doi.org/10.1172/jci.insight.99015CrossRefPubMedCentral

41.

Yuan F-L, Xu M-H, Li X et al (2016) The roles of acidosis in osteoclast biology. Front Physiol 7:222CrossRef

42.

Butt DA, Alharty R, Leu R, Cheung AM (2015) Hypertension, antihypertensive drugs and the risk of fractures. Clin Rev Bone Miner Metab 13:160–172. https://doi.org/10.1007/s12018-015-9191-zCrossRef

43.

Hwang JK, Leu R, Butt DA (2015) Hypertension, antihypertensive drugs, and bone mineral density. Clin Rev Bone Miner Metab 13:149–159. https://doi.org/10.1007/s12018-015-9193-xCrossRef

44.

Ilić K, Obradović N, Vujasinović-Stupar N (2013) The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review. Calcif Tissue Int 92:217–227. https://doi.org/10.1007/s00223-012-9671-9CrossRefPubMed

Titel: Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
verfasst von: Kara L. Holloway-Kew
Amelia G. Betson
Kara B. Anderson
James Gaston
Mark A. Kotowicz
Wan-Hui Liao
Maciej Henneberg
Julie A. Pasco
Publikationsdatum: 01.12.2021
Verlag: Springer London
Erschienen in: Archives of Osteoporosis / Ausgabe 1/2021
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-021-01004-6

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

Abstract

Summary

Purpose

Methods

Results

Conclusions

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Summary

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

FRAX-based osteoporosis treatment guidelines for resource-poor settings in India

Fast kilovoltage (KV)-switching dual-energy CT virtual noncalcium technique using different reconstruction kernels for identifying acute and chronic vertebral compression fractures

A surrogate FRAX model for Pakistan

Bibliometric analysis of global research trends on male osteoporosis: a neglected field deserves more attention

Bone mineral density in healthy adult Indian population: the Chandigarh Urban Bone Epidemiological Study (CUBES)

A country-specific FRAX model for Botswana

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie